Skip to main content
FinSpry Logo
FinSpry
PLX logo
PLX
(NYSEAMERICAN)
Protalix BioTherapeutics, Inc.
$2.37-- (--)
Loading... - Market loading
OverviewFinancialsForecastStatisticsDividendsHistoricalProfile

Protalix BioTherapeutics (PLX) Stock Price & Financial Analysis

Protalix BioTherapeutics Stock Price Chart

Price Chart

Loading chart...

Financial Metrics & Key Statistics

Fundamental metrics, valuation ratios, and profitability indicators

Day's Range$2.32 - $2.39
52-Week High$3.19
52-Week Low$1.41
Open$2.34
Volume448.97K
Average Volume (3M)631.29K
Market Cap196.83M
Shares Outstanding83.05M
P/E Ratio (TTM)12.84
Forward P/E6.25
Price to Sales (P/S)2.58
Price to Book (P/B)2.93
EV/EBITDA7.33
Revenue (TTM)76.38M
Net Income (TTM)15.33M
Free Cash Flow (TTM)13.00M
EPS (TTM)$0.19
Profit Margin20.07%
Operating Margin25.91%
Return on Equity (ROE)22.81%
Debt to Equity0.13
50-Day MA$2.16
200-Day MA$2.22
52-Week Change48.13%
Annual Dividend$0.00
Dividend Yield0.00%
Payout Ratio0.00%

Frequently Asked Questions About Protalix BioTherapeutics

What is the current stock price for PLX?

As of the latest trading session, PLX stock trades at $2.37. The 52-week range is $1.41–$3.19, with a day range of $2.31–$2.38.

What is the P/E ratio for PLX?

Protalix BioTherapeutics's trailing P/E ratio is 12.8, meaning investors pay $12.8 for every $1 of annual earnings. The forward P/E is 6.3, reflecting analyst expectations for future earnings. Protalix BioTherapeutics operates in the Healthcare sector.

Does PLX pay dividends?

Protalix BioTherapeutics does not currently pay a regular dividend. The company reinvests earnings into growth and operations. Check the Dividends tab for historical dividend information.

What do analysts recommend for PLX?

Analyst ratings and recommendations for PLX are displayed in the Analyst Consensus section, including buy/hold/sell distribution and 12-month price targets.

What is the market cap of PLX?

Protalix BioTherapeutics's market capitalization is $196.8M, classifying it as a micro-cap company. Protalix BioTherapeutics operates in the Healthcare sector within the Biotechnology industry.